Diazoxide Choline Controlled-Release Tablet — Competitive Intelligence Brief

Diazoxide Choline Controlled-Release Tablet (Diazoxide Choline Controlled-Release Tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Potassium channel blocker. Area: Cardiovascular.

phase 2 Potassium channel blocker ATP-sensitive potassium channels Cardiovascular Small molecule

Target snapshot

Diazoxide Choline Controlled-Release Tablet (Diazoxide Choline Controlled-Release Tablet) — Essentialis, Inc.. Potassium channel blocker

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Diazoxide Choline Controlled-Release Tablet TARGET	Diazoxide Choline Controlled-Release Tablet	Essentialis, Inc.	phase 2	Potassium channel blocker	ATP-sensitive potassium channels
Minoxidil lotion 2%	Minoxidil lotion 2%	Mae Fah Luang University Hospital	marketed	Potassium channel opener / topical hair growth stimulant	ATP-sensitive potassium channels (KATP); exact follicle-specific target unclear
Sevoflurane (Preconditioning)	Sevoflurane (Preconditioning)	University of Zurich	marketed	Volatile anesthetic with cardioprotective preconditioning properties	Mitochondrial ATP-sensitive potassium channels (mitoKATP); protein kinase C; endothelial nitric oxide synthase
Levosimendan infusion	Levosimendan infusion	AHEPA University Hospital	marketed	Calcium sensitizer / inodilator	Cardiac troponin C; ATP-sensitive potassium channels
metformin, glyburide and glargine	metformin, glyburide and glargine	The University of Texas Health Science Center at San Antonio	marketed	Combination antidiabetic therapy (biguanide + sulfonylurea + basal insulin)	Multiple: AMP-activated protein kinase (metformin), ATP-sensitive potassium channels (glyburide), insulin receptor (glargine)
metformin+ gliclazide	metformin+ gliclazide	GlaxoSmithKline	marketed	Antidiabetic combination (biguanide + sulfonylurea)	Metformin: mitochondrial glycerophosphate dehydrogenase; Gliclazide: ATP-sensitive potassium channels on pancreatic beta cells
Minoxidil lotion 1%	Minoxidil lotion 1%	Mae Fah Luang University Hospital	marketed	Potassium channel opener / topical hair growth stimulant	ATP-sensitive potassium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Potassium channel blocker class)

1. Orphalan · 3 drugs in this class
2. Biogen · 2 drugs in this class
3. Essentialis, Inc. · 1 drug in this class
4. National Center for Research Resources (NCRR) · 1 drug in this class
5. Oregon Health and Science University · 1 drug in this class
6. Sheba Medical Center · 1 drug in this class
7. University of Southern Denmark · 1 drug in this class
8. D'Youville College · 1 drug in this class